OSE Immunotherapeutics’ auto-immunity & inflammation platform consists of two clinical-stage programs with promising candidates focusing on two different pathways:
– the CD28 pathway with FR104
– the IL-7 pathway with OSE-127. OSE-127 is partnered with Servier for its development in ulcerative colitis and Sjögren’s syndrome.
For inflammation, OSE Immunotherapeutics is developing OSE-230, an agonist antibody against ChemR23, also known as chemerin chemokine-like receptor 1 (CMKLR1), known to modulate inflammation. OSE-230 is based on a disruptive concept in the inflammation space – using an antibody-based therapeutic to drive the resolution of the inflammation process rather than targeting and blocking pro-inflammatory signals.
- Target Modality Anti-ChemR23 Agonist
- Indication Resolution of inflammation
- Pre-Clinical POC Ongoing
- Phase 1
- Phase 2
- Phase 3